The June 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities within the academic and vaccine fields in the U.S and abroad. This week, find out about how you can collaborate with Novozymes Biopharma.
SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.
Hitting histone demethylases Joanne Kotz doi:10.1038/scibx.2012.805 A GSK–Structural Genomics Consortium team has identified the first potent and selective histone demethylase inhibitor and shown that the molecule dampens the macrophage inflammatory response. The pharma now is focusing on internal efforts and external approaches to exploring potential therapeutic applications of the inhibitor. Full Text | PDF
Isis takes on myotonic dystrophy Lev Osherovich doi:10.1038/scibx.2012.806 Researchers at the University of Rochester and Isis have come up with an efficient way to treat symptoms of myotonic dystrophy type 1 in mice using systemically delivered antisense oligonucleotides. The finding has fueled an early stage development deal between Isis and Biogen. Full Text | PDF
CXCR2 antagonists in breast cancer Lauren Martz doi:10.1038/scibx.2012.807 A Memorial Sloan-Kettering Cancer Center team has shown that CXC chemokine receptor 2 antagonists sensitized tumors to chemotherapy in mice with metastatic breast cancer. The team is working on additional preclinical studies with the intention of moving the antagonists into clinical trials for breast cancer. Full Text | PDF
Screening for immunogenic cell death Kai-Jye Lou doi:10.1038/scibx.2012.808 French researchers have used a fluorescence-based screening platform to identify small molecules that induced immunogenic cell death in mouse tumors. Next, the group plans to test the best hits in a Phase I/II trial to treat locally invasive head and neck cancers in combination with chemotherapy. Full Text | PDF
Jumonji domain containing 3 (JMJD3; KDM6B); lysine-specific demethylase 6A (KDM6A; UTX) doi:10.1038/scibx.2012.809 An in vitro and cell culture study identified a compound that inhibited the histone demethylases JMJD3 and UTX and that could help treat autoimmune diseases. Full Text | PDF
Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXCL2 (MIP2); CXC chemokine receptor 2 (CXCR2; IL8RB) doi:10.1038/scibx.2012.810 In vitro and mouse studies suggest antagonizing CXCR2 could prevent resistance to chemotherapy and metastasis in breast cancer. Full Text | PDF
BRAF; MEK doi:10.1038/scibx.2012.811 In vitro studies suggest MEK inhibitors could help treat melanomas carrying the BRAF L597 mutation. Full Text | PDF
Mdm4 p53 binding protein homolog (MDM4; MDMX) doi:10.1038/scibx.2012.812 Mouse and cell culture studies suggest antagonizing MDM4 could help treat melanoma. Full Text | PDF
Mammalian target of rapamycin complex 1 (mTORC1); lamin A/C (LMNA) doi:10.1038/scibx.2012.813 In vitro and mouse studies suggest inhibiting mTORC1 could help treat laminopathies including dilated cardiomyopathy. Full Text | PDF
Free fatty acid receptor 1 (FFAR1; GPR40) doi:10.1038/scibx.2012.814 Mouse and in vitro studies have identified GPR40 agonists that could help treat type 2 diabetes. Full Text | PDF
Pyroglutamylated RFamide peptide receptor (QRFPR; GPR103) doi:10.1038/scibx.2012.815 Mouse and in vitro studies suggest a GPR103 agonist could increase food intake to help treat anorexia. Full Text | PDF
Phospholipase A2 group IVA cytosolic calcium-dependent (PLA2G4A; cPLA2-α) doi:10.1038/scibx.2012.816 In vitro studies suggest inhibiting PLA2G4A could help treat HCV infection and dengue fever. Full Text | PDF
Glucose-6-phosphate dehydrogenase (g6pd) doi:10.1038/scibx.2012.817 In vitro studies identified Plasmodium falciparum g6pd inhibitors that could help treat malaria. Full Text | PDF
APAF1 interacting protein (APIP) doi:10.1038/scibx.2012.818 In vitro and genetic sequencing studies suggest reducing APIP expression could help treat systemic inflammatory response syndrome (SIRS), which is a whole-body inflammatory state that can occur in response to infection. Full Text | PDF
β-Site APP-cleaving enzyme 1 (BACE1); amyloid precursor protein (APP) doi:10.1038/scibx.2012.819 Human genetic, cell culture and in vitro assay studies suggest the A673T substitution in APP may protect against AD and normal cognitive decline. Full Text | PDF
NMDAR doi:10.1038/scibx.2012.820 In vitro and mouse studies have identified a hydrogen sulfide (H2S)-releasing NMDAR antagonist that could help treat stroke. Full Text | PDF
Nicotinamide nucleotide adenylyltransferase 1 (NMNAT1) doi:10.1038/scibx.2012.821 Studies with human tissues identified multiple NMNAT1 mutations that could help diagnose Leber's congenital amaurosis (LCA). Full Text | PDF
Unknown doi:10.1038/scibx.2012.822 Mouse studies suggest a photosensitive compound could help treat retinitis pigmentosa (RP). Full Text | PDF
Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1) doi:10.1038/scibx.2012.823 In vitro studies identified CYP11B1 inhibitors that could help treat Cushing's disease. Full Text | PDF
Not applicable doi:10.1038/scibx.2012.824 In vitro and mouse studies suggest preventing formation of neutrophil extracellular traps (NETs) could help prevent thrombosis in patients with cancer. Full Text | PDF
Impact of receptor tyrosine kinase (RTK) ligands on sensitivity of human tumor–derived cell lines to kinase inhibitors doi:10.1038/scibx.2012.825 Analysis of the impact of RTK ligands on sensitivity of human tumor–derived cell lines to kinase inhibitors could guide combination therapy to prevent drug resistance. Full Text | PDF
Stromal and cancer cell coculture system to uncover drug resistance mechanisms and guide combination therapy doi:10.1038/scibx.2012.826 A stromal and cancer cell coculture system could help uncover drug resistance mechanisms and guide combination therapy. Full Text | PDF
Intracellular delivery of therapeutic small interfering RNA with carbonate co-oligomers doi:10.1038/scibx.2012.827 Carbonate co-oligomers for intracellular delivery of therapeutic siRNA could help treat a range of diseases. Full Text | PDF
Nanoparticle vaccines targeted to the large intestine doi:10.1038/scibx.2012.828 Nanoparticle vaccines targeted to the large intestine could help protect against mucosal infections. Full Text | PDF
Systemic delivery of antisense oligonucleotide therapy for myotonic dystrophy type 1 (DM1) doi:10.1038/scibx.2012.829 A study in mice suggests subcutaneous injection of an antisense oligonucleotide could help treat DM1. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment